Hassouna Sally S, Tayel Manal Y, ElKaffash Dalal M, Abdelhady Ahmed M, Elsayed Eman H
Department of Internal Medicine, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Department of Clinical and Chemical Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Open Rheumatol J. 2018 Jul 31;12:115-122. doi: 10.2174/1874312901812010115. eCollection 2018.
To discover the possibility of using microRNA155 (miRNA155) expression level as a biomarker of Behçet's Disease (BD) activity or remission.
Thirty BD patients' white blood cells (WBCs) miRNA155 expression was measured and compared to WBCs miRNA155 expression in 15 healthy subjects. Assessment of disease activity was done using Behçet's Disease Current Activity Form (BDCAF).
miRNA155 expression significantly decreases with the increase of BD activity scored by BDCAF.
Increased miRNA155 may be used as a biomarker of BD remission and thus in the disease follow up. There could be a prospect of treating the disease microRNA 155 effect enhancement.
探讨将微小RNA155（miRNA155）表达水平作为白塞病（BD）活动期或缓解期生物标志物的可能性。
检测30例BD患者白细胞（WBCs）中miRNA155的表达，并与15名健康受试者白细胞中miRNA155的表达进行比较。采用白塞病当前活动形式（BDCAF）评估疾病活动度。
miRNA155表达随BDCAF评分的BD活动度增加而显著降低。
miRNA155升高可作为BD缓解期的生物标志物，从而用于疾病随访。增强微小RNA155的作用可能为该病的治疗带来前景。
